3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
67
Polycystic Ovary Syndrome
3
Neoplasms, Hormone-Dependent
3
Neoplasm Metastasis
2
Carcinoma, Lobular
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Ductal, Breast
2
Breast Diseases
2
Breast Cancer Female
2
Advanced Breast Cancer
2
Sexuality
1
Sexual Dysfunctions, Psychological
1
Osteoporosis
1
Luminal B/HER2-negative Breast Cancer
1
Leiomyoma
1
Infertility
1
Hot Flashes
1
Hormone Receptor Positive Breast Carcinoma
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Fractures, Bone
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Endometrial Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms, Male
1
Breast Carcinoma In Situ
1
Breast Cancer Metastatic
1
Bone Diseases, Metabolic
1
Interventions
Paclitaxel
95
Carboplatin
77
pembrolizumab
74
Cisplatin
29
Bevacizumab
27
Letrozole
22
Radiotherapy
21
Doxorubicin
21
Megestrol Acetate
20
lenvatinib
19
olaparib
18
Taxes
17
Docetaxel
17
Nivolumab
16
Specimen Handling
15
Metformin
15
dostarlimab
14
Magnetic Resonance Spectroscopy
14
Gemcitabine
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
Biopsy
11
temsirolimus
10
abemaciclib
10
atezolizumab
9
Radiation
9
Early Intervention, Educational
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Endometrial Neoplasms
×
Aromatase Inhibitors
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled